A podcast by the Netherlands Innovation Network, hosted from the embassy and consulates in China
Nanjing leads China in Pushing cultured meat. In November 2019scientists from Nanjing Agricultural University created China’s first piece of cultured pork made of stem cells from the muscle tissue of pigs, a milestone in the industry. In this episode we will talk to Dr. Ding’s Shijie, associate professor at the Nanjing Agricultural University in China and CTO at a startup called …
A large number of patients do not respond well to commonly used drugs. Some patients even suffer from side effects. In Europe alone, about 3.5% of hospital admissions are related to side effects of medicines. Many patients are not treated properly because they do not respond or respond poorly to medicines. In this episode, I will talk to Professor Fu. …
Formally, intellectual property rights have been acknowledged and protected in China since the 1980s. In 2001, China became a member of the world trade organization. A premise of this was that China had to address some international concerns about its IPR system. Despite of this, some concerns remain. President Trump has repeatedly called out China for theft of intellectual property. …
The world is fighting two pandemics at the same time – COVID19 and the silent pandemic of antimicrobial resistance (AMR). AMR occurs when bacteria become resistant to antibiotics, making their infections harder to treat. In Europe, approximately 25.000 people die every year because of drug resistant infections. It is estimated that AMR will kill an extra 10 million people globally by 2050. In this episode we …
The world is fighting two pandemics at the same time – COVID19 and the silent pandemic of antimicrobial resistance (AMR). AMR occurs when bacteria become resistant to antibiotics, making their infections harder to treat. In Europe, approximately 25.000 people die every year because of drug resistant infections. It is estimated that AMR will kill an extra 10 million people globally by 2050. In this episode we …
